A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

Sponsor: Bristol-Myers Squibb

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05337137

Patient View

This study assesses the safety and efficacy of nivolumab, relatlimab, and bevacizumab in untreated advanced HCC. Eligible participants must have histologically confirmed HCC, be systemic therapy-naïve, have a Child-Pugh score of 5 or 6, and an ECOG status of 0 or 1. Interventions include specified doses of relatlimab, nivolumab, bevacizumab, and a placebo.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC)
  • Naïve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team)
  • Child-Pugh score of 5 or 6 (ie, Child-Pugh A)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria

  • Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC

  • Prior allogenic stem cell or solid organ transplantation

  • Untreated symptomatic central nervous system (CNS) metastases

  • Clinically significant ascites as defined by:

    i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment

Other protocol-defined inclusion/exclusion criteria apply

Get This Program In Your Inbox

You can sign up and apply your patients for this program.